Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to -$71.2 million.

  • Bicycle Therapeutics' Cash from Operations fell 7868.3% to -$71.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$239.7 million, marking a year-over-year decrease of 1831.49%. This contributed to the annual value of -$164.7 million for FY2024, which is 17169.62% down from last year.
  • Per Bicycle Therapeutics' latest filing, its Cash from Operations stood at -$71.2 million for Q3 2025, which was down 7868.3% from -$72.8 million recorded in Q2 2025.
  • Bicycle Therapeutics' Cash from Operations' 5-year high stood at $34.1 million during Q2 2023, with a 5-year trough of -$86.4 million in Q1 2025.
  • Moreover, its 5-year median value for Cash from Operations was -$26.4 million (2022), whereas its average is -$29.3 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Cash from Operations surged by 31750.63% in 2021 and then crashed by 378604.88% in 2024.
  • Bicycle Therapeutics' Cash from Operations (Quarter) stood at -$10.4 million in 2021, then plummeted by 190.46% to -$30.3 million in 2022, then tumbled by 56.02% to -$47.3 million in 2023, then surged by 80.13% to -$9.4 million in 2024, then crashed by 657.48% to -$71.2 million in 2025.
  • Its Cash from Operations stands at -$71.2 million for Q3 2025, versus -$72.8 million for Q2 2025 and -$86.4 million for Q1 2025.